Journal article
Rituximab capping triggers intracellular reorganisation of B cells
- Abstract:
-
The antibody rituximab, which binds to the protein CD20 on the surface of B-cells, has been used to treat B-cell malignancies for several years. However, the molecular mechanisms underlying this treatment are not yet fully understood. One well-established rituximab-induced mechanism, natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC), has recently been described to involve the polarisation of bound rituximab and CD20 to one side of the B-cell. B-cells polarised ...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Version of record, pdf, 10.4MB)
-
- Publisher copy:
- 10.19185/matters.201612000001
Authors
Funding
Wolfson Foundation
More from this funder
Expand funders...
Bibliographic Details
- Publisher:
- Science Matters Publisher's website
- Journal:
- Matters Journal website
- Publication date:
- 2017-01-01
- Acceptance date:
- 2016-12-29
- DOI:
- ISSN:
-
2297-8240
- Source identifiers:
-
694071
Item Description
- Keywords:
- Pubs id:
-
pubs:694071
- UUID:
-
uuid:3d20ab44-e5ca-4b02-b9af-7a52a232c100
- Local pid:
- pubs:694071
- Deposit date:
- 2017-05-11
Terms of use
- Copyright holder:
- Sezgin et al
- Copyright date:
- 2017
- Notes:
- This observation is distributed under the terms of the Creative Commons Attribution 4.0 International License.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record